Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with castration-resistant prostate cancer (CRPC). However, not all patients respond, and resistance mechanisms are largely unknown. We hypothesized that genomic and transcriptional features from metastatic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Proc Natl Acad Sci U S A
Main Authors: Alumkal, Joshi J., Sun, Duanchen, Lu, Eric, Beer, Tomasz M., Thomas, George V., Latour, Emile, Aggarwal, Rahul, Cetnar, Jeremy, Ryan, Charles J., Tabatabaei, Shaadi, Bailey, Shawna, Turina, Claire B., Quigley, David A., Guan, Xiangnan, Foye, Adam, Youngren, Jack F., Urrutia, Joshua, Huang, Jiaoti, Weinstein, Alana S., Friedl, Verena, Rettig, Matthew, Reiter, Robert E., Spratt, Daniel E., Gleave, Martin, Evans, Christopher P., Stuart, Joshua M., Chen, Yiyi, Feng, Felix Y., Small, Eric J., Witte, Owen N., Xia, Zheng
Formato: Artigo
Idioma:Inglês
Publicado: National Academy of Sciences 2020
Assuntos:
Biological Sciences
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275746/
https://ncbi.nlm.nih.gov/pubmed/32424106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1922207117
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares